Detail Information of Post-Translational Modifications

General Information of Drug Transporter (DT)
DT ID	DTD0491 Transporter Info
Gene Name	SLC9A7
Transporter Name	Sodium/hydrogen exchanger 7
Gene ID	84679
UniProt ID	Q96T83

Post-Translational Modification of This DT
Overview ofSLC9A7 Modification Sites with Functional and Structural Information
Sequence	M E P G D A A R P G S G R A T G A P P P R L L L L P L L L G W G L R V A A A A S A S S S G A A A E D S S A M E E L A T E K E A E E S H R Q D S V S L L T F I L L L T L T I L T I W L F K H R R V R F L H E T G L A M I Y G L I V G V I L R Y G T P A T S G R D K S L S C T Q E D R A F S T L L V N V S G K F F E Y T L K G E I S P G K I N S V E Q N D M L R K V T F D P E V F F N I L L P P I I F H A G Y S L K K R H F F R N L G S I L A Y A F L G T A V S C F I I G N L M Y G V V K L M K I M G Q L S D K F Y Y T D C L F F G A I I S A T D P V T V L A I F N E L H A D V D L Y A L L F G E S V L N D A V A I V L S S S I V A Y Q P A G L N T H A F D A A A F F K S V G I F L G I F S G S F T M G A V T G V N A N V T K F T K L H C F P L L E T A L F F L M S W S T F L L A E A C G F T G V V A V L F C G I T Q A H Y T Y N N L S V E S R S R T K Q L F E V L H F L A E N F I F S Y M G L A L F T F Q K H V F S P I F I I G A F V A I F L G R A A H I Y P L S F F L N L G R R H K I G W N F Q H M M M F S G L R G A M A F A L A I R D T A S Y A R Q M M F T T T L L I V F F T V W I I G G G T T P M L S W L N I R V G V E E P S E E D Q N E H H W Q Y F R V G V D P D Q D P P P N N D S F Q V L Q G D G P D S A R G N R T K Q E S A W I F R L W Y S F D H N Y L K P I L T H S G P P L T T T L P A W C G L L A R C L T S P Q V Y D N Q E P L R E E D S D F I L T E G D L T L T Y G D S T V T A N G S S S S H T A S T S L E G S R R T K S S S E E V L E R D L G M G D Q K V S S R G T R L V F P L E D N A
PTM type	X-N-glycosylation X-Phosphorylation X-Ubiquitination X-Ubiquitination X: Amino Acid

N-glycosylation
Asparagine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC9A7			[1], [2]
Role of PTM	Potential impacts
Modified Residue	Asparagine	Modified Location	145
Experimental Method	Co-Immunoprecipitation
Detailed Description	N-linked Glycosylation at SLC9A7 Asparagine 145 has the potential to affect its expression or activity.
Leucine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Unaffected Membrane trafficking			[3]
Role of PTM	No Significant Effect
Modified Residue	Leucine	Modified Location	515
Modified State	Leucine to Phenylalanine mutation
Experimental Material(s)	Chinese hamster ovary (AP-1) cells
Experimental Method	Co-Immunoprecipitation
Detailed Description	Removal of the N-glycosylation at SLC9A7 Leucine 515 (i.e. Leucine to Phenylalanine mutation) have been reported to have no significant alteration in its membrane trafficking.
Phosphorylation
Serine	9 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC9A7			[4]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	11
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC9A7 Serine 11 has the potential to affect its expression or activity.
PTM Phenomenon2	Have the potential to influence SLC9A7			[5]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	160
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC9A7 Serine 160 has the potential to affect its expression or activity.
PTM Phenomenon3	Have the potential to influence SLC9A7			[5]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	198
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC9A7 Serine 198 has the potential to affect its expression or activity.
PTM Phenomenon4	Have the potential to influence SLC9A7			[6]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	244
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC9A7 Serine 244 has the potential to affect its expression or activity.
PTM Phenomenon5	Have the potential to influence SLC9A7			[7], [8]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	545
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC9A7 Serine 545 has the potential to affect its expression or activity.
PTM Phenomenon6	Have the potential to influence SLC9A7			[7], [9]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	573
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC9A7 Serine 573 has the potential to affect its expression or activity.
PTM Phenomenon7	Have the potential to influence SLC9A7			[10], [11]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	693
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC9A7 Serine 693 has the potential to affect its expression or activity.
PTM Phenomenon8	Have the potential to influence SLC9A7			[10], [11]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	694
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC9A7 Serine 694 has the potential to affect its expression or activity.
PTM Phenomenon9	Have the potential to influence SLC9A7			[11], [12]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	695
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC9A7 Serine 695 has the potential to affect its expression or activity.
Threonine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC9A7			[11], [12]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	691
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC9A7 Threonine 691 has the potential to affect its expression or activity.
Tyrosine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC9A7			[13], [14]
Role of PTM	Potential impacts
Modified Residue	Tyrosine	Modified Location	556
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC9A7 Tyrosine 556 has the potential to affect its expression or activity.
Ubiquitination
Lysine	2 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	.			[15]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	692
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC9A7 Lysine 692 has the potential to affect its expression or activity.
PTM Phenomenon2	Have the potential to influence SLC9A7			[16]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	709
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC9A7 Lysine 709 has the potential to affect its expression or activity.

References
1	Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins. Nat Biotechnol. 2009 Apr;27(4):378-86.
2	Molecular cloning and characterization of a novel (Na+,K+)/H+ exchanger localized to the trans-Golgi network. J Biol Chem. 2001 May 18;276(20):17387-94.
3	A recurrent missense variant in SLC9A7 causes nonsyndromic X-linked intellectual disability with alteration of Golgi acidification and aberrant glycosylation. Hum Mol Genet. 2019 Feb 15;28(4):598-614.
4	iTRAQ labeling is superior to mTRAQ for quantitative global proteomics and phosphoproteomics. Mol Cell Proteomics. 2012 Jun;11(6):M111.014423.
5	Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics. 2014 Jul;13(7):1690-704.
6	Phosphoproteomics Profiling of Nonsmall Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator. Proteomics. 2017 Nov;17(22):10.1002/pmic.201700214.
7	A Methodological Assessment and Characterization of Genetically-Driven Variation in Three Human Phosphoproteomes. Sci Rep. 2018 Aug 14;8(1):12106.
8	Phosphoproteomic screening identifies physiological substrates of the CDKL5 kinase. EMBO J. 2018 Dec 14;37(24):e99559.
9	Improved Method for Determining Absolute Phosphorylation Stoichiometry Using Bayesian Statistics and Isobaric Labeling. J Proteome Res. 2017 Nov 3;16(11):4217-4226.
10	Robust, Reproducible, and Economical Phosphopeptide Enrichment Using Calcium Titanate. J Proteome Res. 2019 Mar 1;18(3):1411-1417.
11	Capillary Zone Electrophoresis-Tandem Mass Spectrometry for Large-Scale Phosphoproteomics with the Production of over 11,000 Phosphopeptides from the Colon Carcinoma HCT116 Cell Line. Anal Chem. 2019 Feb 5;91(3):2201-2208.
12	Combined inhibition of receptor tyrosine and p21-activated kinases as a therapeutic strategy in childhood ALL. Blood Adv. 2018 Oct 9;2(19):2554-2567.
13	Ultra-deep tyrosine phosphoproteomics enabled by a phosphotyrosine superbinder. Nat Chem Biol. 2016 Nov;12(11):959-966.
14	Sensitive, Robust, and Cost-Effective Approach for Tyrosine Phosphoproteome Analysis. Anal Chem. 2017 Sep 5;89(17):9307-9314.
15	15 years of PhosphoSitePlus?: integrating post-translationally modified sites, disease variants and isoforms. Nucleic Acids Res. 2019;47(D1):D433-D441.
16	Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell. 2011 Oct 21;44(2):325-40.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.

Detail Information of Post-Translational Modifications

Visitor Map

Correspondence